Sign Out
Glycaemic control: Adults: JARDIANCE DUO is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: when treatment with both empagliflozin and metformin is appropriate (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions and Dosage & Administration).
Inadequately controlled with metformin or empagliflozin alone.
Inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin.
Already treated with empagliflozin and metformin co-administered as separate tablets.
Paediatric population: JARDIANCE DUO is indicated as an adjunct to diet and exercise to improve glycaemic control in children aged 10 years and above with type 2 diabetes mellitus: when treatment with both empagliflozin and metformin is appropriate.
Inadequately controlled with metformin alone or in combination with insulin (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions).
Already treated with empagliflozin and metformin co-administered as separate tablets.
Prevention of cardiovascular events: Empagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions).
To prevent cardiovascular deaths, empagliflozin should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.
